drugset / Trial / NCT02111603

Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids

NCT02111603

NaSingle-groupOpen-labelTreatment

Summary

The investigators' hypothesis is that therapy with Colesevelam, reduces fecal bile acid excretion in patients with Irritable Bowel Syndrome (IBS)-diarrhea with prior evidence of increased fecal 48 hour total bile acid excretion. The investigators aim to study the ability of the HPLC assay for fecal bile acids to demonstrate responsiveness after treatment with Colesevelam.

Timeline

Start
2014-04
Primary completion
2014-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Colesevelam Other / unclassified 1875 mg Oral